Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study

Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study

<b>Objective</b>: The objective of this study was to assess clinical decision-making associated with the use of a multi-analyte blood biomarker (BBM) test among patients presenting with signs or symptoms of mild cognitive impairment or dementia. <b>Methods</b>: The Quality Im...

Full description

Saved in:
Bibliographic Details
Main Authors: Mark Monane, Demetrius M. Maraganore, Robert M. Carlile, Kim G. Johnson, David A. Merrill, Darren R. Gitelman, Kenneth S. Sharlin, Lawren A. VandeVrede, Kristi K. George, Jimin Wang, Tim West, Leslie Jacobs, Philip B. Verghese, Joel B. Braunstein
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Diagnostics
Subjects:
Alzheimer’s disease
blood biomarker
diagnosis
clinical decision-making
clinical utility
memory care specialists
Online Access:https://www.mdpi.com/2075-4418/15/2/167
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2075-4418/15/2/167

Similar Items